[Therapeutic use of intravenous immunoglobulins in the antiphospholipid syndrome].

Abstract

Although experience remains limited and uncontrolled, intravenous immunoglobulin (IVIg) therapy probably has a place in the management of selected patients with the antiphospholipid syndrome. It seems effective for the prevention of recurrent pregnancy losses when conventional strategies using subcutaneous heparin and low-dose aspirin have failed. IVIg are currently investigated in the treatment of recurrent in vitro fertilization failure associated with antiphospholipid antibodies. In patients with severe thrombocytopenia, IVIg usually induce a prompt but transient remission. Finally, IVIg associated with steroids and heparin might improve survival in the rare but life-threatening catastrophic antiphospholipid syndrome.

• Authors: J C Piette, D Lê Thi Huong, B Wechsler
• Journal: Annales de medecine interne (Ann Med Interne (Paris)) Vol. 151 Suppl 1 Pg. 1S51-4 (May 2000) ISSN: 0003-410X [Print] France
• Vernacular Title: Utilisation thérapeutique des immunoglobulines intraveineuses au cours du syndrome des anti-phospholipides.
• PMID: 10896991 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Anticoagulants
• Immunoglobulins, Intravenous
• Platelet Aggregation Inhibitors
• Heparin
• Aspirin

Topics

• Abortion, Habitual (etiology, prevention & control)
• Abortion, Spontaneous (etiology, prevention & control)
• Anticoagulants (therapeutic use)
• Antiphospholipid Syndrome (complications, therapy)
• Aspirin (therapeutic use)
• Female
• Fertilization in Vitro
• Heparin (therapeutic use)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Platelet Aggregation Inhibitors (therapeutic use)
• Pregnancy
• Thrombocytopenia (therapy)